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While the catalog of mammalian transcripts and their
expression levels in different cell types and disease
states is rapidly expanding, our understanding of
transcript function lags behind. We present a robust
technology enabling systematic investigation of the
cellular consequences of repressing or inducing
individual transcripts. We identify rules for specific
targetingof transcriptional repressors (CRISPRi), typi-
cally achieving 90%–99% knockdown with minimal
off-target effects, and activators (CRISPRa) to endog-
enous genes via endonuclease-deficient Cas9. To-
gether they enable modulation of gene expression
over a 1,000-fold range. Using these rules, we
construct genome-scale CRISPRi and CRISPRa li-
braries, each of which we validate with two pooled
screens. Growth-based screens identify essential
genes, tumor suppressors, and regulators of differen-
tiation. Screens for sensitivity to a cholera-diphtheria
toxin provide broad insights into the mechanisms of
pathogen entry, retrotranslocation and toxicity. Our
results establish CRISPRi and CRISPRa as powerful
tools that provide rich and complementary informa-
tion for mapping complex pathways.INTRODUCTION
Dramatic advances in sequencing technology have cataloged a
universe of transcribed loci—greatly exceeding the number of
canonical protein-coding open reading frames (ORFs)—which
collectively are responsible for carrying out the instructions en-coded by the genome (Djebali et al., 2012). A central challenge
now is to understand the biological role of these transcripts
and how quantitative differences in their expression define
cellular states in normal development and in disease. Despite
intense efforts, the function of many protein-coding genes re-
mains poorly defined. Even less is known about the biological
roles of most noncanonical transcripts such as enhancer
RNAs, upstream antisense RNAs, lncRNAs, or other intergenic
RNAs (Cech and Steitz, 2014). Efforts to address this deficiency
in our knowledge would be greatly aided by techniques that are
capable of dynamically and precisely controlling the expression
of individual transcripts.
One way to explore the function of genes is to disrupt their ex-
pression through repression. The dominant tool for programmed
knockdown of mRNAs is RNA interference (RNAi) (Chang et al.,
2006). However, RNAi has pervasive problems with off-target
effects, which can be especially confounding in the context of
large-scale screens (Adamson et al., 2012; Jackson et al., 2003;
Sigoillot et al., 2012). Additionally, because RNAi is mediated by
cytoplasmic argounaute proteins, gene silencing through this
approach is best suited to depletion of cytosolic mRNA targets.
An alternative emerging strategy is the use of programmable
genome editing methods that permanently delete or modify DNA
using designable, sequence-specific endonucleases such as
zinc finger, transcription activator-like effector (TALE) nucleases,
or CRISPR (clustered regularly interspaced short palindromic
repeats)/Cas9 (CRISPR-associated protein 9) proteins (Gaj et al.,
2013; Sander and Joung, 2014). A series of elegant studies
recently exploited the readily programmable nature of Cas9, in
which the specificity is determined by a short guide (sg)RNA, to
enable genome-scale loss-of-function screens (Koike-Yusa
et al., 2014; Shalem et al., 2014;Wang et al., 2014). These studies
established CRISPR-mediated cutting as a powerful screening
technology complementary to RNAi and haploid mutagenesis
screens (Carette et al., 2009).Nonetheless, screening approachesCell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 647
based on genome editing are currently focused on loss-of-func-
tion studies involving irreversible frameshift disruptions, limiting
their utility for the study of essential genes and long noncoding
RNAs. Additionally, double-stranded DNA breaks can be cyto-
toxic (Huang et al., 1996; Jackson, 2002). Finally, indels formed
from error-prone DNA repair are often short and in-frame, which
could limit the ability to disable all of the alleles of a gene.
A programmable DNA-binding protein that can recruit an
effector domain to turn transcription on and off in a dynamic
and quantitative manner offers, in principle, a more flexible tool
for interrogating the many transcripts in complex genomes. Pio-
neering experimentswith designed chimeric zinc finger and TALE
proteins fused to transcription effector domains demonstrate that
such an approach can modulate transcription of endogenous
genes (Beerli et al., 1998, 2000; Zhang et al., 2011). However,
as each transcript target requires a unique fusion protein, ex-
panding these methods to genome-scale is arduous.
Recently, we and others have used catalytically inactive Cas9
(dCas9) fusion proteins guided by gene-specific sgRNAs to
localize effector domains to specific DNA sequences to either
repress (CRISPRi) or activate (CRISPRa) transcription of target
genes (Gilbert et al., 2013; Sander and Joung, 2014). To date, a
small number of sgRNAs have been tested, leaving unanswered
whether CRISPRi/a is a feasible strategy for globally interrogating
gene function and, if so, how best to target a gene to activate or
repress transcription while minimizing off-target effects.
Here, we describe the development and application of a
method for high-specificity, genome-scale modulation of tran-
scription of endogenous genes in human cells using CRISPRi/a.
To accomplish this, we first performed a saturating screen in
which we tested the activity of every unique sgRNA broadly tiling
around the transcription start sites (TSSs) of 49 genes known to
modulate cellular susceptibility to ricin (Bassik et al., 2013). From
this, we extracted distinct rules for regions where either CRISPRi
or CRISPRa maximally changes the expression of endogenous
genes, as well as rules for predicting off-target effects, providing
an algorithm to design two genome-scale libraries targeting each
gene with 10 sgRNAs. We validated these libraries by screening
for genes that control cell growth and response to a chimeric
cholera/diphtheria fusion toxin (CTx-DTA) (Guimaraes et al.,
2011). These experiments demonstrate that our CRISPRi/a
screening platform is robust, showing high reproducibility and
activity with undetectable intrinsic toxicity. More generally, we
establish that transcriptional repression is inducible, reversible,
and can target essential genes. We demonstrate that we can
use CRISPRi and CRISPRa to control transcript levels for endog-
enous genes across a wide dynamic range. We also provide
extensive evidence that properly designed CRISPRi reagents
are highly specific. As such, these methods represent transfor-
mative tools for defining transcript function across the breadth
of transcripts encoded by the human genome.
RESULTS
A High-Throughput Tiling Screen Defines Rules
for CRISPRi Activity at Endogenous Genes
CRISPRi can repress transcription by directly blocking RNA po-
lymerase activity (dCas9) or through effector domain-mediated648 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.transcriptional silencing (dCas9-KRAB) (Gilbert et al., 2013; Qi
et al., 2013). In order to better understand and optimize CRISPRi
activity, we used a pooled high-throughput screen to define rules
that determine CRISPRi repression of endogenous genes. We
targeted 49 genes that we had previously shown to modulate
cellular susceptibility to the AB toxin ricin (Bassik et al., 2013).
The extent of gene repression for these genes typically has a
monotonic relationship with the ricin-resistance phenotype,
allowing us to use a ricin-resistance score calculated by moni-
toring sgRNA frequencies in a pooled screen to indirectly mea-
sure transcriptional repression.
Using massively parallel oligonucleotide synthesis, we gener-
ated a library of sgRNAs that tile theDNA in a 10-kilobasewindow
around the TSS of these 49 genes (54,810 total sgRNAs) (Bassik
et al., 2009) (Figure 1A). We also included 1,000 negative control
sgRNAs derived from scrambled sequences corresponding to
the same windows.
Wepackaged this tiling library of sgRNAs into lentiviral particles
and transduced K562 human myeloid leukemia cells stably ex-
pressing dCas9 or a dCas9-KRAB fusion protein, which we
have previously described (Gilbert et al., 2013). We harvested
populations of cells expressing the library either at the outset of
the experiment, after growth under standard conditions, or
following ricin treatment. We then counted the frequency of
each sgRNA in the library in each sample using deep sequencing
todeterminehoweachsgRNA in the librarymodulates cell growth
and cellular susceptibility to ricin phenotypes. We defined these
phenotypes quantitatively as gamma (g) and rho (r), respectively
(See Figure S1A, available online, and Kampmann et al., 2013).
Many sgRNAs potently repress gene expression, as evi-
denced by their impact on ricin sensitivity (Figures 1B and
S2A). Plotting this data for all 49 genes showed that active
sgRNAs cluster around or just downstream from the TSS of
each gene for dCas9-KRAB and dCas9, respectively (Figure 1C).
We saw that strong CRISPRi activity is obtained by targeting
dCas9-KRAB to a window of DNA from 50 to +300 bp relative
to the TSS of a gene, with a maximum in the 50–100 bp region
just downstream of the TSS (Figures 1C and 1D). This suggested
that optimal activity leverages the combined activity of dCas9
interference along with repression from the KRAB domain. We
also observed that sgRNAs with protospacer lengths of 18–21
base pairs were significantly more active than sgRNAs contain-
ing longer protospacers (Figure S2B). Nucleotide homopolymers
had a strongly negative effect on sgRNA activity (Figure S2D).
However, neither the DNA strand that was targeted nor the
sgRNA GC content across a broad range strongly correlated
with sgRNA activity (Figures S2C and S2E).
To evaluate the feasibility of genome-scale genetic screens
based on CRISPRi, we compared the strength of phenotypes
obtained with CRISPRi to our previously published shRNA
data. We applied the rules described above to data from our
sgRNA tiling library to select all sgRNAs predicted to be highly
active and then randomly subsampled sets of 10 or 24 sgRNAs.
We calculated a normalized phenotype Z score by dividing mean
phenotypes for each gene by the standard deviation of sgRNA
phenotypes from the nontargeting control set (Figure S1B). We
see significant ricin phenotypes for each of the 49 genes. More-
over, in virtually every case the normalized ricin phenotype
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Figure 1. A Tiling sgRNA Screen Defines Rules for CRISPRi Activity at Endogenous Genes in Human Cells
(A) Massively parallel determination of growth or toxin-resistance phenotypes caused by sgRNAs in mammalian cells expressing dCas9 or dCas9 fusion
constructs.
(B) UCSC genome browser tracks showing the genomic organization, GC content, and repetitive elements around the TSS of a representative gene, VPS54,
across a 10 kb window targeted by the tiling sgRNA library. sgRNA ricin-resistance phenotypes (as Z scores, see Figure S1 and Experimental Procedures) in
dCas9 and dCas9-KRAB expressing K562 cells are depicted in black on the top and bottom, respectively. See also Figure S2A for more examples.
(C) Sliding-window analysis of all 49 genes targeted in a tiling sgRNA library. Green line: median sgRNA activity in a defined window for all genes. Orange region:
observed average window of maximum CRISPRi activity. Data displayed as a phenotype signed Z score, excluding all guides longer than 22 bp.
(D) CRISPRi activity for all 49 genes in defined windows relative to the TSS of each gene.
(E) Ricin-resistance phenotypes, comparing CRISPRi sgRNAs selected by our rules to RNAi, for genes previously established to cause ricin-resistance phe-
notypes when knocked down by RNAi. Mean ± SD phenotype-signed Z score of 100 sets of 10 randomly subsampled sgRNAs or shRNAs. See also Figure S2F.
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Figure 2. CRISPRi Activity is Highly Sensi-
tive to Mismatches Between the sgRNA
and DNA sequence
On- and off-target activity of dCas9, dCas9-KRAB
and Cas9 for sgRNAs with a varying number and
position of mismatches. Off-target activity of
sgRNAs with mismatches is displayed as percent
of the on-target activity for the corresponding
sgRNA without mismatches. Asterisk indicates
sgRNAs with three, four, or five mismatches
randomly distributed across region 3 of the sgRNA
sequence. Data are displayed for each mismatch
position as the mean of all sgRNAs with that
mismatch; see Figure S3 for individual sgRNA
activities. sgRNAs were included in the analysis
only if the fully matched guide was highly active
(phenotype-signed Z scoreR 4); n = 5 for dCas9,
n = 11 for dCas9-KRAB, and n = 10 for Cas9.Z score or p value is stronger (in many cases far stronger) than
seen with a comparably-sized shRNA library (generated by sub-
sampling our published data) (Figures 1E and S2F).
CRISPRi Transcriptional Silencing Is Highly Sensitive
to Mismatches between the Target DNA Site
and the sgRNA
To assess CRISPRi off-target activity at endogenous genes, we
selected a set of 30 sgRNAs from our tiling library (6 sgRNAs/
gene targeting five genes). For each of these sgRNAs, we tested
the activity of a series of derivative sgRNAs with a variable num-
ber and position of mismatches (Figure 2). This experiment al-
lowed us to measure the relative amount of gene repression
for sgRNAs with or without mismatch base pairing targeting
the same DNA locus. We found that even a single mismatch at
the 30 end of the protospacer decreased CRISPRi activity on
average, while combinations of mismatches that pass our off-
target filter abolished activity (Figures 2, and S3, and Extended
Experimental Procedures). From this analysis, we concluded
that properly designed CRISPRi sgRNAs have minimal off-target
transcriptional repression activity.
A High-Throughput Tiling Screen Defines Rules for
CRISPRa Activity at Endogenous Genes
We recently developed an improved CRISPRa method, termed
sunCas9, in which expression of a single sgRNAwith one binding
site is sufficient to robustly activate transcription (Tanenbaum
et al., 2014, this issue). In the sunCas9 system, a single dCas9
fusion protein bound to DNA recruits multiple copies of the650 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.activating effector domain, thus am-
plifying our ability to induce transcription
(Figure 3A).
To define rules for optimal CRISPRa
sgRNA design, we used our tiling library,
which targets genes capable of modu-
lating cellular sensitivity to ricin. We previ-
ously showed for several of the genes in
this tiling library that knockdown and
plasmid overexpression resulted in oppo-site ricin phenotypes (Bassik et al., 2013). For example, knock-
down of SEC23B sensitized cells to ricin, whereas SEC23B over-
expression desensitized cells to ricin. These observations
suggested that we should be able to observe reversed pheno-
types in this tiling screen arising from CRISPRa activity.
We transduced K562 cells stably expressing the sunCas9 sys-
tem (Figure 3A) with the sgRNA tiling library and screened for
ricin phenotypes as described for CRISPRi above. Analysis of
data for individual genes or averaged data for all 49 genes
demonstrated that many sgRNAs for each gene affected ricin
resistance (Figures 3B, S4A, and S4B). Our negative control
sgRNAs showed very little activity and were not correlated be-
tween biological replicate screens, suggesting that CRISPRa
activity is specific. We observed a peak of active sgRNAs for
CRISPRa at400 to50 bp upstream from the TSS (Figure 3B).
This activity pattern fits with a model in which each VP16 domain
can bind the mediator complex and recruit basal transcription
machinery, activating transcription when spaced appropriately
from a TSS (Mittler et al., 2003). With this system, we have shown
we can turn on genes that are poorly expressed and increase the
expression of well-expressed genes (Figure 3E). Overall, our
CRISPRi/a tiling screens provide rules for how CRISPRi/a con-
trols expression of endogenous genes.
An Allelic CRISPRi/a Series of Transcript Activation and
Repression Shows that Protein Abundance Dynamically
Modulates the Cellular Response to Ricin
For many genes, we do not know how the relative abundance
of the encoded protein relates to its function. We observed a
marked anticorrelation in our ricin screens between CRISPRa
phenotypes and CRISPRi phenotypes for individual genes (Fig-
ure 3C). As the genes targeted by our tiling library were selected
based on a knockdown phenotype, all genes showed pheno-
types in the CRISPRi screen, but only a subset showed pheno-
types in the CRISPRa screen.
To validate results from both the CRISPRi and CRISPRa tiling
screens, we selected an allelic series of sgRNAs by phenotype
from the screen and retested each sgRNA individually (38 sgRNAs
targeting four genes). Our results show that our CRISPRi/a
screens produced reliable phenotype scores, robustly repro-
duced upon retesting, and that CRISPRi/a can activate and
repress the transcription of endogenous genes over a wide
dynamic range (up to 1,000-fold) (Figures 3D and 3E), enabling
systematic interrogation of how gene dosage controls cellular
functions of interest.
A Robust and Highly Specific Genome-Scale CRISPRi
Screening Platform
The results of our tiling CRISPRi screen established our ability
to pick active sgRNAs with low off-target activity and provided
a set of rules enabling us to design a robust genome-scale sgRNA
library. We chose a library size of 10 sgRNAs/gene for the
following reasons. Over half of the sgRNAs conforming to these
rules gave clear ricin phenotypes. For a library with 10 sgRNAs/
gene, 94% of the genes would thus have 2 or more highly active
sgRNAs. Finally, computational subsampling of the phenotypic
data from our tiling library data to 10 sgRNAs/gene and calcula-
tion of Z scores for hit genes indicated that a library with 10
sgRNAs/gene would reliably detect hit genes (Figure 1E).
We synthesized and cloned a genome-scale CRISPRi sgRNA
library targeting 15,977 human protein-coding genes (10
sgRNAs/TSS, targeting 20,898 TSS) with 11,219 nontargeting
control sgRNAs for a total of 206,421 sgRNAs (Table S2). To eval-
uate this library, we first screened for genes essential for cell
growth in K562 cells. Briefly, K562 cells stably expressing
dCas9-KRAB were transduced in replicate with the entire
genome-scale library, and each replicate was grown for 10 days
at a minimum library coverage of 3,750 cells/sgRNA in a single
spinner flask.
To characterize our screening methodology and library
design, we examined the correlation between screen replicates.
Individual sgRNAs reproducibly showed dramatic depletion (up
to 256-fold) over a 10 day screen, demonstrating that individual
sgRNAs can have profound effects on cell growth (Table S2) (Fig-
ure 4A). The distribution of our negative control sgRNAswas very
narrow with little correlation between replicates (Spearman R =
0.036), suggesting that the off-target activity of these controls
is very low (Figure 4A). Indeed, 99.7% of our negative controls
had no detectable activity. The observed specificity is consistent
with our previously published RNA-seq data (Gilbert et al., 2013).
To further explore the prevalence of off-target effects, we
examined two classes of genes not expected to show any on-
target activity in our screen: olfactory receptors and genes on
the Y chromosome. The sgRNAs that target these genes were
designed and picked in the same manner as the rest of the
library; however, olfactory receptors should not be expressed
in this cell type and, as K562 cells are derived from a femaledonor, sgRNAs that target genes on the Y chromosome lack a
DNA target. As with the negative controls, these genes show
no phenotype on average and exhibit very little correlation be-
tween replicates (Spearman R = 0.057 for olfactory genes and
0.052 for Y targeting) (Figure 4A). We also observed no evi-
dence of nonspecific toxicity due to expression of dCas9-
KRAB and our sgRNA library in K562 cells, suggesting that
dCas9 bound to the genome is not toxic under these conditions
(Figure 4B). Thus, CRISPRi is highly specific and nontoxic.
To identify hit genes in this screen, we used a metric of
average growth phenotype (g) for the top three sgRNAs for
each gene (see Experimental Procedures and Table S3). Among
the top hits were genes involved in essential cellular functions,
including translation, transcription, and DNA replication (Figures
4C and S5A) (Huang et al., 2009a, 2009b), thus validating our
approach as a screening platform.
A Genome-Scale CRISPRa Screening Platform
The results of our CRISPRa tiling screen established our ability to
confidently measure gene phenotypes resulting from inducing
expression with single sgRNAs. As with the CRISPRi tiling
screens, our data enabled the development of a set of rules
that allowed construction of a genome-scale CRISPRa library.
Many of these rules overlapped with those of CRISPRi (e.g.,
sgRNA length and sequence preferences). A key difference is
that the optimal window for targeting sgRNAs for CRISPRa lies
upstream of the TSS (Figure 3B). We therefore constructed an in-
dependent CRISPRa library, designing 10 sgRNAs between
400 to50 base pairs upstream of each TSS for 15,977 human
genes, along with 5,968 nontargeting control sgRNAs, for a total
of 198,810 sgRNAs.
We evaluated our CRISPRa platform in a screen for genes that
affect cell growth when induced in K562 cells constitutively ex-
pressing the sunCas9 system. Replicate screens were conduct-
ed as described above. Themagnitude of growth defects seen in
our CRISPRa screen was comparable to that of the above
CRISPRi screen, although fewer sgRNAs caused a growth
phenotype (Figure S5B and Table S2). We analyzed control
sgRNAs with no genomic target or Y chromosome targets and
found minimal phenotypes, which lacked substantial correlation
between experimental replicates (Spearman R = 0.155 and R =
0.010, respectively), indicating that the phenotype distribution
observed in nontargeting controls was primarily a result of sto-
chastic noise rather than off-target effects. Furthermore, the
fraction of cells expressing sgRNAs and the sunCas9 system
was stable over the course of the experiment, indicating that
there was no general toxicity associated with the CRISPRa
platform (Figure 4B). These data suggest that, like CRISPRi,
CRISPRa is specific and nontoxic.
Defining Regulators of Survival and Differentiation
in Human Cells by CRISPRa
We then investigated the genes whose induction caused cells to
deplete over the course of our CRISPRa screen. We scored
genes by the average g of the three most active sgRNAs as
above, and compared these phenotypes to those observed in
the CRISPRi screen (Figure 4D and Table S3). The results from
the two screens had little overlap, suggesting that few genesCell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 651
AB
D E
C
p 
va
lu
e)
Z 
sc
or
e)
(legend on next page)
652 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.
are both essential and toxic upon induction and that wild-type
expression levels of genes are generally optimal for K562
growth. Whereas CRISPRi hits are naturally limited to expressed
genes, CRISPRa hits included genes across a broad range of
endogenous expression levels (Figure S5D). We observed that
the majority of genes that inhibited growth in the CRISPRa
screen fell into three overlapping classes.
The first class was tumor suppressor genes: 18 of the top 50
genes, including six of the top seven, are known to have potent
tumor suppressor activity (Vogelstein et al., 2013; Zhao et al.,
2013). These genes include p53-related protein TP73, cell cycle
inhibitors CDKN1C (p57) and CDKN1A (p21), apoptotic factors
BAK1 and BCL2L11 (BIM), and chromatin remodeling factor
ARID1A (Figure 4D and Table S4). Gene set enrichment analysis
(GSEA) confirmed this observation, highlighting several genes
important in the intrinsic pathway of apoptosis or in chronic
myeloid leukemia (CML) homeostasis consistent with the origin
of K562 cells as a clonal isolate from a CML blast crisis (ATCC)
(Figure 4E). Similarly, top gene ontology annotations included
‘‘positive regulation of apoptosis’’ and ‘‘regulation of cell cycle’’
(Figure S5C). While tumor suppressors are classically consid-
ered to be mutated early in cancer progression (Vogelstein
et al., 2013), these results demonstrate than many potential tu-
mor suppressor genes remain functional but downregulated
and suggest that CRISPRa can be used to pinpoint intact path-
ways and vulnerabilities in tumor cells.
Transcription factor families with well-established roles in tis-
sue development and differentiation represent another class of
growth hits, accounting for 16 of the top 50 genes (K562 cells
have known potential to undergo erythroid differentiation). These
genes include CCAAT/Enhancer-binding proteins (CEBP), Ho-
meobox genes, Forkhead box genes, Ikaros family zinc finger
proteins, and hematopoietic differentiation factor SPI1 (PU.1)
(Figure 4D and Table S4) (Spitz and Furlong, 2012). This observa-
tion is reflected in enriched annotations relating to multicellu-
larity, cell differentiation, and development (Figure S5C).
The complementary nature of the CRISPRi and CRISPRa
screens is nicely illustrated by results from two gene pairs
(SPI1/GATA1 and CEBPA/CEBPG) in which one member of
each pair inhibits the function of the other. GATA1 and CEBPG
were strong hits in the CRISPRi screen, consistent with their
roles as inhibitors of myeloid differentiation. By contrast, both
SPI1 and CEBPA were robust hits in our CRISPRa activation
screen. These observations are consistent with the inhibitory
functions of SPI1 and CEBPA: silencing of CEBPA leads toFigure 3. A Tiling sgRNA Screen Defines Rules for CRISPRa Activity a
(A) A schematic of the dCas9-SunTag + scFV-VP64 + sgRNA system for CRISPR
(B) Activity of sgRNAs in K562 cells stably expressing each component of CRISPR
(Phenotype-signed Z scores; therefore, negative values represent opposite res
window analysis of all 49 genes targeted by our tiling library in green. Green line,
were excluded. See also Figure S4.
(C) CRISPRa phenotypes andCRISPRi (dCas9-KRAB) phenotypes are anticorrela
CRISPRi/a sgRNA activity relative to a negative control distribution for 24 sub
displayed.
(D) CRISPRi knockdown and CRISPRa activation of the same gene can have op
validation experiments (mean ± SD of 3 replicates).
(E) Modulation of expression levels for 3 genes by CRISPRi and CRISPRa as quan
replicates) measured for each sgRNA.derepression of CEBPG (Alberich-Jorda` et al., 2012) and the
protein encoded by SPI1 (PU.1) is a direct binding partner of
GATA-1 and inhibits its transcriptional activity (Zhang et al.,
2000).
Finally, several hit genes have key roles in mitosis. PLK4 con-
trols centrosome duplication, and overexpression of the gene in
U2OS cells leads to increased centriole number (Habedanck
et al., 2005). The proteins encoded by KIF18B and KIF2C form
a complex that destabilizes microtubules during mitosis (Tanen-
baum et al., 2011).
Overall, the results from our paired CRISPRi/a growth screens
demonstrate that complementary information can be obtained
by loss- and gain-of-function genetic screens, and highlight
the utility of the platform for future studies into tumor biology
and cell differentiation.
Dynamically Controlling Gene Expression with CRISPRi
The ability to reversibly tune the expression of select transcripts
would be a powerful tool for evaluating transcript function. To
evaluate the applicability of CRISPRi to this purpose, we cloned
a lentiviral expression construct that places an optimized
KRAB-dCas9 fusion protein under the control of a doxycy-
cline-inducible promoter (Figures 5A and 5B). Induced expres-
sion of KRAB-dCas9 robustly depletes transcript levels from
sgRNA-targeted genes (Figures 5C and S5E). To further assess
dynamic control of CRISPRi, we inducibly repressed several
genes identified in our genome-scale CRISPRi growth screen
(Figure S5G). Cells that express sgRNAs targeting these essen-
tial genes showed almost no growth phenotype in the absence
of doxycycline, but rapidly and robustly disappeared from the
population upon addition of doxycycline (Figure 5D). Addition-
ally, gene repression and resulting phenotypes were reversible
(Figures 5C, S5E, and S5F), indicating that KRAB-dCas9 does
not create a permanently repressive chromatin state at targeted
promoters.
To test our ability to dynamically control expression of essen-
tial genes on a larger scale, we cloned a sublibrary targeting 426
manually curated genes (10 sgRNAs/TSS or 4,923 targeting
sgRNAs plus 750 nontargeting controls). This library was trans-
duced into K562 cells stably expressing our inducible KRAB-
dCas9 fusion protein, and cell growth effects were then evalu-
ated in the presence and absence of doxycycline. Only four
sgRNAs were depleted strongly in the absence of doxycycline;
however, with induction of KRAB-dCas9, many sgRNAs were
strongly depleted (Figure 5E). Negative control sgRNAs againt Endogenous Genes in Human Cells
a.
a, as a function of the distance of the sgRNA site to the TSS of the targeted gene
ults than from knockdown). Top, sgRNAs targeting VPS54; Bottom, sliding-
median activity; orange, window of maximal activity. Guides longer than 22 bp
ted for select genes. For each gene, aMann-Whitney p value is calculated using
sampled sgRNAs. Mean ± SD p value of 100 randomly subsampled sets is
posing effects on ricin resistance in both primary screens and single sgRNA
tified by qPCR plotted against the ricin-resistance phenotype (mean ± SD of 3
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Figure 4. Genome-Scale CRISPRi and CRISPRa Screens Reveal Genes Controlling Cell Growth
(A) sgRNA phenotypes from a genome-scale CRISPRi screen for growth in human K562 cells (black). Three classes of negative control sgRNAs are color-coded:
nontargeting sgRNAs (gray), sgRNAs targeting Y-chromosomal genes (green) and sgRNAs targeting olfactory genes (orange).
(B) Coexpression of sgRNAs and dCas9-KRAB or dCas9-SunTag + scFV-VP64 is not toxic in K562 cell lines over 16 days.
(C) Gene set enrichment analysis (GSEA) for hits from the CRISPRi screen. A histogram of gene distribution is shown under the GSEA curve.
(D) CRISPRi versus CRISPRa gene phenotypes for genome-scale growth screens (black). For the 50 genes in the CRISPRa screen with the most negative growth
phenotype, each gene was annotated and labeled based on evidence of activity as a tumor suppressor (orange), developmental transcription factor (green), or in
regulation of the centrosome (purple). Two additional CRISPRi hit genes that are discussed in the text are labeled in red. See Table S4 for annotations and
references.
(E) GSEA for hits from the CRISPRa growth screen. A histogram of gene distribution is shown under the GSEA curve.produced a narrow distribution of phenotypes with little correla-
tion between biological replicates with or without doxycycline.
Additionally, we found no evidence that targeted KRAB-dCas9654 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.generally impedes cell growth (Figure 5F). Taken together,
these results demonstrate CRISPRi is nontoxic, inducible and
reversible.
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Figure 5. CRISPRi Gene Silencing Is Inducible, Reversible, and Nontoxic
(A) Expression construct encoding an inducible KRAB-dCas9 fusion protein.
(B) Western blot analysis of inducible KRAB-dCas9 in the absence, presence, and after washout of doxycycline.
(C) Relative RAB1A expression levels (as quantified by qPCR) in inducible CRISPRi K562 cells transduced with RAB1A-targeting sgRNAs in the absence,
presence, and after washout of doxycycline. Mean ± standard error of technical replicates (n = 2) normalized to control cells (assayed in the presence of
doxycycline) from the day 2 time point.
(D) Competitive growth assays performed with inducible CRISPRi K562 cells transduced with the indicated sgRNAs in the presence and absence of doxycycline.
Data are represented as the mean ± SD of replicates (n = 3). See also Figure S5G.
(E) A CRISPRi sublibrary screen for effects on cell growth was performed with inducible CRISPRi K562 cells in the presence and absence of doxycycline.
(F) Cumulative growth curves from the sublibrary screen represented in (E) show no bulk changes to growth caused by induction of KRAB-dCas9. Mean ± SD of
replicate infections each screened in duplicate.AGenome-Scale CRISPRi ScreenReveals Pathways and
Complexes that Govern Response to Cholera and
Diphtheria Toxin
To test the performance of our CRISPRi approach for detecting
genes controlling a more complex cellular phenotype, we per-formed a genome-scale CRISPRi screen for genes thatmodulate
sensitivity to a chimeric toxin composed of the diphtheria toxin
catalytic A subunit covalently linked to cholera toxin (CTx-DTA,
Figure 6A). This chimera had been previously developed to pro-
vide a growth readout for cholera intoxication (Guimaraes et al.,Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 655
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Figure 6. Genome-Scale CRISPRi and CRISPRa Screens Reveal Known and New Pathways and Complexes Governing the Response to a
Cholera-Diphtheria Fusion Toxin
(A) Model for CTx-DTA binding, retrograde trafficking, retrotranslocation, and cellular toxicity.
(B) Overview of top hit genes detected by the CTx-DTA screen. Dark red and blue circles: Top 50 sensitizing and protective hits, respectively. Light red and blue
circles: further hits that fall into the same protein complexes or pathways as top 50 hits. Circle area is proportional to phenotype strength. White stars denote
genes identified in a previous haploid mutagenesis screen (Guimaraes et al., 2011). See also Figure S6 for hit gene names.
(C) CRISPRi and CRISPRa hits in sphingolipid metabolism. Display as in (B), except that the left and right sides of each circle represent the phenotypes in the
CRISPRi and CRISPRa screens, respectively.
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2011). Some aspects of both cholera and diphtheria toxin entry
and toxicity are well characterized, but open questions remain.
The cell surface receptor for cholera toxin is the GM1a ganglio-
side (Van Ness et al., 1980). After endocytosis, the toxin traffics
via the Golgi to the endoplasmic reticulum (ER), fromwhich it ret-
rotranslocates into the cytosol, possibly through the ER-associ-
ated degradation (ERAD) machinery. Once in the cytosol, the
DTA moiety ADP-ribosylates the diphthamide residue in Elonga-
tion Factor 2, halting translation and killing the cell (Figure 6A).
K562 cells expressing the CRISPRi sgRNA library and dCas9-
KRAB were either grown under standard conditions or treated
with several pulses of CTx-DTA over the course of 10 days.
We observed highly correlated enrichment and depletion of
many sgRNAs between replicates, indicating that CRISPRi can
identify genes that modulate both resistance and sensitivity to
a selective pressure (Table S2).
We ranked genes by the average phenotype of their three
strongest sgRNAs (Table S3, and Figures 6B and S6). GSEA re-
vealed that KEGGpathways enriched for top protective hit genes
were ‘‘Infection with Vibrio cholerae’’ and ‘‘Glycosphingolipid
biosynthesis, ganglio-series’’ (Figure S7B), while gene sets for
top sensitizing genes included ‘‘ribosome’’ and ‘‘proteasome’’
(Figure S7B). Since the diphtheria toxin catalytic subunit inhibits
translation, depletion of the ribosome can be expected to sensi-
tize cells to the toxin. Disruption of the proteasome also sensi-
tizes cells to CTx-DTA, suggesting that the cytosolic toxin is a
substrate for proteasomal degradation. Taken together, the un-
biased GSEA analysis provides support for the high specificity
in hit gene identification by our CRISPRi approach.
We further defined the 50 hits with the strongest protective ef-
fect and the 50 hits with the strongest sensitizing effect as ‘‘top
hits’’ (all of these phenotypes are far outside of the range seen
with otherwise matched negative control sgRNAs). We charac-
terized these genes by assigning them to cellular pathways
and protein complexes according to their previously character-
ized roles (Figures 6B and S6). Our CRISPRi screen identified a
protective effect of knockdown for all top hits recovered in the
previously published haploid mutagenesis screen (white stars
in Figure 6B). The two top pathways identified by haploid muta-
genesis as modulating cellular sensitivity to CTx-DTA are the
diphthamide biosynthetic pathway (required to generate eEF-
2-diphthamide, the target of diphtheria toxin) and the ganglioside
biosynthetic pathway (required to produce GM1a, the cell-sur-
face receptor for cholera toxin). Our screen also identified
many additional core components of each pathway. While
knockdown of all hits in the diphthamide biosynthesis pathway
had a protective effect, the results for ganglioside biosynthesis
genes showed a more complex pattern: knockdown of enzymes
involved in the production of GM1a were protective, whereas
knockdown of enzymes that catalyze the production of other
gangliosides (including GM1b) was sensitizing. These results
provide genetic confirmation that GM1a is the relevant cell-sur-
face receptor for CTx-DTA and more broadly illustrate the value
of being able to reliably detect both sensitizing and protective
genes to dissect biological pathways.
Many of the top hits are components of cellular pathways and
protein complexes previously identified in experiments to be
important for retrograde trafficking and retrotranslocation ofother toxins such as ricin and Shiga toxin (Bassik et al., 2013;
Smith et al., 2009). Retrotranslocation of the catalytic chain of
CTx has been proposed to be mediated by the ER-associated
degradation (ERAD) pathway, although this pathway was not
identified in previous genetic screens. Consistent with this pro-
posed role for the ERAD machinery, knockdown of members
of the ERAD E3 ubiquitin ligase complex, SYVN1 (encoding
Hrd1) and SEL1L (the mammalian homolog of yeast Hrd3),
rendered cells resistant to CTx-DTA. Factors that mediate cyto-
solic degradation of ERAD substrates (in particular UBXN4, also
known as UBXD2 or erasin, and the proteasome) appeared as
sensitizing hits, suggesting that they may reduce cytosolic levels
of the toxin’s catalytic subunit in WT cells.
To validate the suggested role of the identified ERAD factors in
toxin retrotranslocation from the ER to the cytosol, we quantified
the amount of CTx chains in the cytosol andmembrane fractions.
As expected,SEL1L knockdown resulted in a dramatic reduction
of cytosolic CTx-A1, whereas levels in the membrane fraction
were much less affected (Figures 7A–7C). By contrast, knock-
down of B4GALNT1, an enzyme required for the synthesis of
the CTx receptor GM1a, resulted in a nearly complete absence
of CTx chains from both the cytosolic and themembrane fraction
(Figures 7A–7C).
An open question in CTx biology is how the toxin traverses the
Golgi network (Wernick et al., 2010). Our screen revealed that
COG and GARP complexes, which tether late endosomes to
the trans-Golgi network or modulate intra-Golgi retrograde
transport (Bonifacino and Rojas, 2006) are critical host factors
for CTx-DTA. These and other complexes and pathways we
identify here (Figure 6B), including several involved in RNA pro-
cessing, had not previously been linked to cholera toxin biology,
highlighting the potential of CRISPRi as a discovery platform.
Importantly, many top hits—even those not previously impli-
cated in cholera or diphtheria pathogenesis—were tightly clus-
tered in well-defined protein complexes and pathways. For
several of these, the vast majority of components were hits, sug-
gesting that CRISPRi screens can approach saturation.
Potent Phenotypes and Knockdown Levels Achieved by
the Genome-Scale CRISPRi Library
To validate the results from this screen, we retested sgRNAs that
putatively modulate cellular response to CTx-DTA in mechanis-
tically diverse ways. For each sgRNA, we quantified both the
ricin phenotypes as well as the change in abundance of the tar-
geted transcript by qPCR. Our retest experiments were highly
correlated with data from the primary screen (Figure 7D). In our
validation experiments for the tiling ricin screen and the
genome-scale CTx-DTA screen, the activities of 71 out of 72
sgRNAs were robustly confirmed and were highly correlated
(R2 = 0.879) with the results obtained in the primary screen.
Finally, analysis of mRNA levels by qPCR data showed robust
repression, with 80%–99% knockdown for each sgRNA and
at least 90% for every gene (Figure 7E).
AGenome-ScaleCRISPRaScreenofCholera-Diphtheria
Toxin Complements and Extends CRISPRi Results
To further explore the biological insights gained from CRISPRa
screening, we performed a genome-scale CRISPRa screen forCell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 657
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Figure 7. CRISPRi Strongly Represses Gene Expression of Both Protein-Coding and Noncoding Genes, Resulting in Reproducible
Phenotypes
(A–C) Cells expressing a negative control sgRNA or an sgRNA targeting SEL1L or B4GALNT1 were incubated with cholera toxin and fractionated to quantify
cholera toxin present in the cytosolic and membrane fractions by western blot. B4GALNT1 repression blocks toxin uptake, whereas SEL1L repression prevents
toxin retrotranslocation from the membrane fraction to the cytosol.
(D) Validation of CTx-DTA screen phenotypes with single sgRNA retest experiments. Data are represented as the mean ± SD of replicates (n = 3).
(E) CRISPRi knockdown of 13 hit genes (28 sgRNAs; sgRNAs correspond to 7D) identified in the CTx-DTA screen was quantified by qPCR. The gray shaded
region denotes sgRNAs showing at least 90% knockdown for each gene. Data are normalized to a negative control sgRNA (NC).
(F) CRISPRi knockdown of 6 lncRNA genes was quantified by qPCR. Two to three sgRNAs computationally predicted to target each gene were cloned and
transduced into K562 cells expressing dCas9-KRAB. Data are normalized to a negative control sgRNA (NC).
(G) K562 cells expressing dCas9-KRAB were transduced with either a nontargeting sgRNA or an sgRNA targeting the XIST locus (sgXIST-1). The cells were then
stained with DAPI and an RNA FISH probe for the XIST transcript. Two hundred nonapoptotic interphase cells in each condition were scored for XIST RNA
coating. XIST is undetectable in cells transduced with sgXIST-1. Scale bar, 5 mm.genes that modulate sensitivity to CTx-DTA (Tables S2 and S3).
As with the CRISPRi screen, GSEA revealed the specificity of the
detected hits (Figure S7B). For some of the top hits, CRISPR-
mediated transcriptional activation and repression caused
opposite phenotypes (e.g., enzymes in ganglioside biosynthesis,658 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.Figure 6C), similar to what we observed for genes controlling
ricin sensitivity (Figure 3C).
CRISPRaalso revealedadditional andhighly complementary in-
formation, as illustrated by analysis of glycosphingolipid biosyn-
thesis pathways. Induction of enzymes in the neolacto branch of
sphingolipid biosynthesis protected cells from CTx-DTA (Figures
6C and S7A and S7C). This pathway is a parallel branch to the
ganglioside branch, which produces the CTx-DTA receptor
GM1a. Our findings suggest that upregulation of the neolacto
branch diverts the common precursor lactosylceramide away
from the ganglioside branch. Similarly, upregulation of the sulfa-
tide-generatingenzymeGAL3ST1hasaprotectiveeffect, presum-
ablybydivertingceramide fromthesphingolipid to thecerebroside
pathway (Figure 6C). These results highlight the capacity of
CRISPRa to complementCRISPRi by querying the consequences
of upregulating pathways that may otherwise be inactive.
Effective Knockdown of Noncoding RNAs
Finally, we investigatedwhether CRISPRi was able to repress the
transcription of long noncoding RNAs (lncRNAs), a class of tran-
scripts that have been difficult to systematically perturb by other
methods (Bassett et al., 2014). Using our CRISPRi library design
algorithm, we selected and cloned up to three sgRNAs each tar-
geting six characterized lncRNAs (GAS5,H19,MALAT1,NEAT1,
TERC, XIST) (Geisler and Coller, 2013) with good evidence of
expression in K562 cells. We transduced the sgRNAs into cells
expressing dCas9-KRAB and quantified the amount of transcript
knockdown by qPCR. We achieved >80% knockdown for all but
one of the lncRNA genes tested (Figure 7F). Overall, more than
50% of the sgRNAs yielded >85% knockdown. We confirmed
the strong repression of XIST by RNA fluorescence in situ hybrid-
ization (FISH) and observed no residual expression along the X
chromosome (Figure 7G). These results demonstrate that
CRISPRi can effectively repress lncRNA expression, enabling
future systematic studies of noncoding gene function.
DISCUSSION
Here, we establish CRISPRi and CRISPRa as robust tools for
systematically manipulating transcription of endogenous genes
in human cells. We demonstrate that CRISPRi/a can be used
to rapidly screen for both loss-of-function and gain-of-function
phenotypes in a pooled format. We identify both known and un-
expected genes that control growth of K562 cells or that modu-
late sensitivity to a toxin (CTx-DTA). We also show that we can
use CRISPRi/a to create allelic series of gene expression, span-
ning a broad range from100-fold repression to10-fold induc-
tion, allowing us to define how the abundance of a protein or
transcript relates to its function.
A key feature of CRISPRi is the low incidence of off-target ef-
fects, as evidenced by the near-absence of activity for three large
and distinct classes of negative control sgRNAs in our genome-
scale CRISPRi library. This feature simplifies validation and in-
terpretation of screening results. The observed specificity likely
stems from two distinct properties of our system. First, CRISPRi/a
complexes bound outside a narrow window around the TSS
largely fail to modulate transcription; this dramatically shrinks the
sequence space across the genome where off-target binding
could produce significant off-target activity. Second, CRISPRi ac-
tivity is highly sensitive to mismatches between the sgRNA and
target DNA, suggesting that off-target binding of dCas9 observed
in ChIP-seq experiments is too transient to impact transcription
(Duan et al., 2014; Kuscu et al., 2014; Wu et al., 2014).CRISPRa screening provides a new approach for exploring
the diversity of transcripts across complex genomes. Gene acti-
vation has been used to dissect the limiting component of a
biochemical process, identify the molecular target of a drug, or
activate key rate-limiting steps in a pathway (Davis et al., 1987;
Rine et al., 1983). Recently, a combinatorial cDNA overexpres-
sion screen identified genes that, when coexpressed, reprogram
fibroblasts into pluripotent stem cells (Takahashi and Yamanaka,
2006). CRISPRa should greatly accelerate similar searches for
combinations of factors with emergent properties. In addition,
CRISPRa will likely provide insight into cellular pathways where
redundancy hampers loss-of-function genetic approaches.
CRISPRa will also enable the exploration of cellular states in
which otherwise inactive pathways are induced, and thereby
reveal functional coupling within complex cellular networks and
suggest potential therapeutic strategies.
Our ability to control transcriptionwith high specificity simplifies
the analysis and validation of high-throughput screening data.
The genome-scale CRISPRi and CRISPRa libraries described
here contain 10 sgRNAs per TSS. The resulting library size allows
each to be screened in a population of 200million cells, which can
be easily grown in a single spinner flask. Furthermore, the
observed high specificity and an improved understanding of rules
governing sgRNA activity should enable us to create even more
compact sgRNA libraries. Additionally, an sgRNA library designed
to activate or repress a broader range of transcripts in the human
genome could reveal the function of many noncanonical RNAs
encoded in the human genome. As most noncoding transcripts
are nuclear and lack an open reading frame,methods that directly
modulate transcription are optimally suited for interrogating the
function of these RNAs (Derrien et al., 2012).
Systematic genetic interaction (GI) maps are powerful tools for
revealing gene functions within pathways or complexes (Bassik
et al., 2013; Boone et al., 2007; Costanzo et al., 2010). A
CRISPRa GI map or a combined CRISPRi/a GI map could yield
rich novel biology and help elucidate how networks of proteins
dictate cellular function. More generally, quantitative methods
of turning on and off one or multiple transcripts represent a crit-
ical tool for understanding how expression of the genes encoded
in our genomes controls cell function and fate.EXPERIMENTAL PROCEDURES
CRISPRi/a Libraries
Tiling Libraries
sgRNAswere designed targeting 49 genes (see Figure 1E) previously identified
in shRNA screens as having ricin-resistance phenotype (Bassik et al., 2013). All
possible sgRNAs within a 10 kb window around the gene TSS and meeting
certain criteria were included (see Extended Experimental Procedures). Nega-
tive controls were designed based on scrambled sequences from these 10 kb
windows and filtered by the same criteria as targeting sgRNAs.
Genome-Scale CRISPRi/a Libraries
Genes were selected from the entire set of protein-coding genes, although a
subset of genes with a RPKM of 0 in a K562 cell RNA-seq expression data
set were excluded. sgRNAs conforming to rules including low predicted off-
targets and minimal length (see Figure S2 and Extended Experimental Proce-
dures) were selected from a window of 50 to +300 bp (CRISPRi) or 400 to
50 bp (CRISPRa) with respect to the TSS. Negative controls we designed in
the same way based on scrambled sequence derived from the same window
of several hundred genes.Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 659
Library Cloning
Oligonucleotides encoding sgRNAs designed as described above were syn-
thesized as pooled libraries. These were then cloned into lentiviral vectors
for expression from a U6 promoter (see Extended Experimental Procedures).
Cell Line Construction
For constitutive and inducible CRISPRi screens, polyclonal cells expressing
dCas9/KRAB fusion proteins driven from an SFFV or TRE3G promoter,
respectively, were generated by viral transduction. For CRISPRa screens, a
clonal cell line expressing dCas9-SunTag and a scFV-sfGFP-VP64 fusion
was generated (See Extended Experimental Procedures).
Growth and Toxin Screens
Cells were grown at minimum library coverage of 1,000 for tiling screens and
3,750 for genome-scale screens. For growth screens, cells were grown in spin-
ner flasks and harvested at 0 and 10 days after puromycin selection. For toxin
screens, cells were treated with pulses of ricin or CTx-DTA (Bassik et al., 2013;
Guimaraes et al., 2011) and harvested when sufficient selective pressure rela-
tive to untreated cells had been applied. Briefly, DNA was isolated, the
cassette encoding the sgRNA was amplified by PCR, and relative sgRNA
abundance was determined by next generation sequencing as previously
described (Bassik et al., 2013; Kampmann et al., 2014).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and four tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2014.09.029.
AUTHOR CONTRIBUTIONS
B.A., L.A.G., M.A.H., M.K., J.S.W. were primarily responsible for the concep-
tion, design, and interpretation of the experiments and wrote the manuscript.
B.A., Y.C., L.A.G., M.A.H., M.K., J.E.V., and E.H.W. conducted experiments.
L.A.G. cloned dCas9 chimeras and sgRNA expression constructs, con-
structed cell lines, carried out tiling screens, and conducted validation exper-
iments. M.A.H. designed libraries, carried out tiling and genome-scale
screens, and analyzed screen data. B.A. constructed the inducible cell line
and conducted all inducible experiments. C.G. and H.L.P. contributed to
CTx-DTA studies. B.P. contributed to XIST studies. M.C.B. and L.S.Q. contrib-
uted to the conception and interpretation of the experiments.
ACKNOWLEDGMENTS
The authors thank M. Tanenbaum, J. Tsai, K. Kostova, J. Zalatan, W. Lim, S.
Weissman, J. Doudna, and R. Vale for unpublished reagents, technical advice
and helpful discussion. L.S.Q. acknowledges support from the UCSF Center
for Systems and Synthetic Biology. This work was supported by NIH P50
GM102706 (J.S.W.), NIH P50 GM081879 (L.S.Q., E.H.W.), NIH U01
CA168370 and NIH R01 DA036858 (J.S.W.), as well as the Howard Hughes
Medical Institute (J.E.V., Y.C., M.K., M.A.H., J.S.W.). B.A. is an HHMI Fellow
of the Damon Runyon Cancer Research Foundation (DRG-[2182-14]). L.A.G.
is a Fellow of the Leukemia and Lymphoma Society. M.A.H. is supported by
the UCSF Medical Scientist Training Program. M.K. is supported by NCI/NIH
Pathway to Independence Award K99CA181494.
Received: July 15, 2014
Revised: September 3, 2014
Accepted: September 16, 2014
Published: October 9, 2014
REFERENCES
Adamson, B., Smogorzewska, A., Sigoillot, F.D., King, R.W., and Elledge, S.J.
(2012). A genome-wide homologous recombination screen identifies the RNA-
binding protein RBMX as a component of the DNA-damage response. Nat.
Cell Biol. 14, 318–328.660 Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc.Alberich-Jorda`, M., Wouters, B., Balastik, M., Shapiro-Koss, C., Zhang, H., Di
Ruscio, A., Radomska, H.S., Ebralidze, A.K., Amabile, G., Ye, M., et al. (2012).
C/EBPg deregulation results in differentiation arrest in acutemyeloid leukemia.
J. Clin. Invest. 122, 4490–4504.
Bassett, A.R., Akhtar, A., Barlow, D.P., Bird, A.P., Brockdorff, N., Duboule, D.,
Ephrussi, A., Ferguson-Smith, A.C., Gingeras, T.R., Haerty, W., et al. (2014).
Considerations when investigating lncRNA function in vivo. eLife 3, e03058.
Bassik, M.C., Lebbink, R.J., Churchman, L.S., Ingolia, N.T., Patena, W., LeP-
roust, E.M., Schuldiner, M., Weissman, J.S., andMcManus,M.T. (2009). Rapid
creation and quantitative monitoring of high coverage shRNA libraries. Nat.
Methods 6, 443–445.
Bassik, M.C., Kampmann, M., Lebbink, R.J., Wang, S., Hein, M.Y., Poser, I.,
Weibezahn, J., Horlbeck, M.A., Chen, S., Mann, M., et al. (2013). A systematic
mammalian genetic interactionmap reveals pathways underlying ricin suscep-
tibility. Cell 152, 909–922.
Beerli, R.R., Segal, D.J., Dreier, B., and Barbas, C.F., 3rd. (1998). Toward
controlling gene expression at will: specific regulation of the erbB-2/HER-2
promoter by using polydactyl zinc finger proteins constructed from modular
building blocks. Proc. Natl. Acad. Sci. USA 95, 14628–14633.
Beerli, R.R., Dreier, B., and Barbas, C.F., 3rd. (2000). Positive and negative
regulation of endogenous genes by designed transcription factors. Proc.
Natl. Acad. Sci. USA 97, 1495–1500.
Bonifacino, J.S., and Rojas, R. (2006). Retrograde transport from endosomes
to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7, 568–579.
Boone, C., Bussey, H., and Andrews, B.J. (2007). Exploring genetic interac-
tions and networks with yeast. Nat. Rev. Genet. 8, 437–449.
Carette, J.E., Guimaraes, C.P., Varadarajan,M., Park, A.S., Wuethrich, I., God-
arova, A., Kotecki, M., Cochran, B.H., Spooner, E., Ploegh, H.L., and Brum-
melkamp, T.R. (2009). Haploid genetic screens in human cells identify host
factors used by pathogens. Science 326, 1231–1235.
Cech, T.R., and Steitz, J.A. (2014). The noncoding RNA revolution-trashing old
rules to forge new ones. Cell 157, 77–94.
Chang, K., Elledge, S.J., and Hannon, G.J. (2006). Lessons from Nature: mi-
croRNA-based shRNA libraries. Nat. Methods 3, 707–714.
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S.,
Ding, H., Koh, J.L.Y., Toufighi, K., Mostafavi, S., et al. (2010). The genetic land-
scape of a cell. Science 327, 425–431.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000.
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., Guer-
nec, G., Martin, D., Merkel, A., Knowles, D.G., et al. (2012). The GENCODE v7
catalog of human long noncoding RNAs: analysis of their gene structure, evo-
lution, and expression. Genome Res. 22, 1775–1789.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A.,
Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of
transcription in human cells. Nature 489, 101–108.
Duan, J., Lu, G., Xie, Z., Lou, M., Luo, J., Guo, L., and Zhang, Y. (2014).
Genome-wide identification of CRISPR/Cas9 off-targets in human genome.
Cell Res. 24, 1009–1012.
Gaj, T., Gersbach, C.A., and Barbas, C.F., 3rd. (2013). ZFN, TALEN, and
CRISPR/Cas-based methods for genome engineering. Trends Biotechnol.
31, 397–405.
Geisler, S., and Coller, J. (2013). RNA in unexpected places: long non-coding
RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14,
699–712.
Gilbert, L.A., Larson, M.H., Morsut, L., Liu, Z., Brar, G.A., Torres, S.E., Stern-
Ginossar, N., Brandman, O., Whitehead, E.H., Doudna, J.A., et al. (2013).
CRISPR-mediated modular RNA-guided regulation of transcription in eukary-
otes. Cell 154, 442–451.
Guimaraes, C.P., Carette, J.E., Varadarajan, M., Antos, J., Popp, M.W., Spoo-
ner, E., Brummelkamp, T.R., and Ploegh, H.L. (2011). Identification of host cell
factors required for intoxication through use of modified cholera toxin. J. Cell
Biol. 195, 751–764.
Habedanck, R., Stierhof, Y.-D., Wilkinson, C.J., andNigg, E.A. (2005). The Polo
kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 7, 1140–1146.
Huang, L.C., Clarkin, K.C., and Wahl, G.M. (1996). Sensitivity and selectivity of
the DNA damage sensor responsible for activating p53-dependent G1 arrest.
Proc. Natl. Acad. Sci. USA 93, 4827–4832.
Huang, W., Sherman, B.T., and Lempicki, R.A. (2009a). Systematic and inte-
grative analysis of large gene lists using DAVID bioinformatics resources.
Nat. Protoc. 4, 44–57.
Huang, W., Sherman, B.T., and Lempicki, R.A. (2009b). Bioinformatics enrich-
ment tools: paths toward the comprehensive functional analysis of large gene
lists. Nucleic Acids Res. 37, 1–13.
Jackson, S.P. (2002). Sensing and repairing DNA double-strand breaks. Carci-
nogenesis 23, 687–696.
Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao,M.,
Li, B., Cavet, G., and Linsley, P.S. (2003). Expression profiling reveals off-
target gene regulation by RNAi. Nat. Biotechnol. 21, 635–637.
Kampmann, M., Bassik, M.C., and Weissman, J.S. (2013). Integrated platform
for genome-wide screening and construction of high-density genetic interac-
tion maps in mammalian cells. Proc. Natl. Acad. Sci. USA 110, E2317–E2326.
Kampmann, M., Bassik, M.C., and Weissman, J.S. (2014). Functional geno-
mics platform for pooled screening and generation of mammalian genetic
interaction maps. Nat. Protoc. 9, 1825–1847.
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, Mdel.C., and Yusa, K.
(2014). Genome-wide recessive genetic screening in mammalian cells with a
lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267–273.
Kuscu, C., Arslan, S., Singh, R., Thorpe, J., and Adli, M. (2014). Genome-wide
analysis reveals characteristics of off-target sites bound by the Cas9 endonu-
clease. Nat. Biotechnol. 32, 677–683.
Mittler, G., Stu¨hler, T., Santolin, L., Uhlmann, T., Kremmer, E., Lottspeich, F.,
Berti, L., and Meisterernst, M. (2003). A novel docking site on Mediator is crit-
ical for activation by VP16 in mammalian cells. EMBO J. 22, 6494–6504.
Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P.,
and Lim, W.A. (2013). Repurposing CRISPR as an RNA-guided platform for
sequence-specific control of gene expression. Cell 152, 1173–1183.
Rine, J., Hansen, W., Hardeman, E., and Davis, R.W. (1983). Targeted selec-
tion of recombinant clones through gene dosage effects. Proc. Natl. Acad.
Sci. USA 80, 6750–6754.
Sander, J.D., and Joung, J.K. (2014). CRISPR-Cas systems for editing, regu-
lating and targeting genomes. Nat. Biotechnol. 32, 347–355.
Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S.,
Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., and Zhang, F. (2014).
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science
343, 84–87.Sigoillot, F.D., Lyman, S., Huckins, J.F., Adamson, B., Chung, E., Quattrochi,
B., and King, R.W. (2012). A bioinformatics method identifies prominent off-
targeted transcripts in RNAi screens. Nat. Methods 9, 363–366.
Smith, R.D., Willett, R., Kudlyk, T., Pokrovskaya, I., Paton, A.W., Paton, J.C.,
and Lupashin, V.V. (2009). The COG complex, Rab6 and COPI define a novel
Golgi retrograde trafficking pathway that is exploited by SubAB toxin. Traffic
10, 1502–1517.
Spitz, F., and Furlong, E.E.M. (2012). Transcription factors: from enhancer
binding to developmental control. Nat. Rev. Genet. 13, 613–626.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Tanenbaum, M.E., Macurek, L., van der Vaart, B., Galli, M., Akhmanova, A.,
and Medema, R.H. (2011). A complex of Kif18b and MCAK promotes microtu-
bule depolymerization and is negatively regulated by Aurora kinases. Curr.
Biol. 21, 1356–1365.
Tanenbaum, M.E., Gilbert, L.A., Qi, L.S., Weissman, J.S., and Vale, R.D.
(2014). A versatile protein tagging system for signal amplification in single
molecule imaging and gene regulation. Cell 159, this issue, 635–646.
Van Ness, B.G., Howard, J.B., and Bodley, J.W. (1980). ADP-ribosylation of
elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ri-
bosyl-amino acid and its hydrolysis products. J. Biol. Chem. 255, 10717–
10720.
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr.,
and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–
1558.
Wang, T., Wei, J.J., Sabatini, D.M., and Lander, E.S. (2014). Genetic screens in
human cells using the CRISPR-Cas9 system. Science 343, 80–84.
Wernick, N.L.B., Chinnapen, D.J.-F., Cho, J.A., and Lencer, W.I. (2010).
Cholera toxin: an intracellular journey into the cytosol by way of the endo-
plasmic reticulum. Toxins (Basel) 2, 310–325.
Wu, X., Scott, D.A., Kriz, A.J., Chiu, A.C., Hsu, P.D., Dadon, D.B., Cheng, A.W.,
Trevino, A.E., Konermann, S., Chen, S., et al. (2014). Genome-wide binding of
the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32,
670–676.
Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K.A., Mueller, B.U., Narravula,
S., Torbett, B.E., Orkin, S.H., and Tenen, D.G. (2000). PU.1 inhibits GATA-1
function and erythroid differentiation by blocking GATA-1 DNA binding. Blood
96, 2641–2648.
Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M., and Arlotta, P. (2011).
Efficient construction of sequence-specific TAL effectors for modulating
mammalian transcription. Nat. Biotechnol. 29, 149–153.
Zhao, M., Sun, J., and Zhao, Z. (2013). TSGene: a web resource for tumor sup-
pressor genes. Nucleic Acids Res. 41 (Database issue), D970–D976.Cell 159, 647–661, October 23, 2014 ª2014 Elsevier Inc. 661
